PR: Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Ladenburg, Germany, 4 April 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), will present promising preclinical data from its Amanitin-based ADC HDP-103 targeting metastatic castration‑resistant prostate cancer (mCRPC) at the American Association of Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, USA, from 17 to 22 April.
Details of the conference and poster presentation are as follow:
Poster: HDP-103, a PSMA targeting amanitin-based ADC, is efficacious even in difficult to treat patient derived xenograft models with heterogenous PSMA expression
|
Poster number: |
5639 |
|
Session: |
Antibody-Drug Conjugates and Linker Engineering 4 |
|
Presentation time: |
21 April, 2:00 pm – 5:00 pm PDT |
|
Link to abstract: |
https://www.abstractsonline.com/pp8/#!/21436/presentation/5438 |
HDP-103 demonstrates target specific binding in human tissues and robust and durable antitumor activity in patient-derived xenograft (PDX) models representative of mCRPC, including tumors with heterogeneous PSMA expression and those harboring a del(17p). In these models, Amanitin-based HDP-103 was superior to an anti-PSMA Exatecan ADC. Adverse events with HDP-103 in non-human primates were restricted to known off-target effects of Amanitin-based ADCs, primarily in the liver and kidney. These effects can be readily monitored and are transient. HDP-103 serum levels demonstrate stability of the ADC in circulation, no evidence of drug accumulation, no differences between sexes, and dose-linearity.
The potent anti-tumor efficacy of HDP-103 combined with a favorable half-life and a manageable safety profile, leads to a comfortable therapeutic index (TI) of HDP-103 that is well in the range of other ADCs that are approved or in development for solid tumor indications. Taken together, these data warrant further clinical development of HDP-103 as a novel treatment option for mCRPC. HDP-103´s unique mode of action gives it advantages over other treatment modalities in use or development for mCRPC including in patients with del(17p) who have a high unmet medical need.